Education
About Us
Working with TipRanks
Follow Us
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
NRXP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.10 - $6.01
Previous CloseN/A
Volume2.07M
Average Volume (3M)186.39K
Market Cap
$34.68M
Enterprise Value$23.57M
Total Cash (Recent Filing)$267.19K
Total Debt (Recent Filing)$61.00M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
May 20, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding16,915,648
10 Day Avg. Volume163,781
30 Day Avg. Volume186,386
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.98
Forecast
1Y Price Target
$18.50Price Target Upside793.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
NRX Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Earnings PotentialNRx Pharmaceuticals is targeting achievement of $100M in revenue in 2025 and could become profitable with just $38M in revenue.
Market OpportunityAccording to market research, the anti-suicide market is projected to reach $5B by 2026, indicating a significant opportunity for NRx to capture market share with NRX-100.
Strategic PartnershipsNRX-100 has attracted interest from a commercial-stage pharmaceutical company, providing NRx with an opportunity to consider non-binding terms for an out-licensing and distribution agreement potentially worth up to $300M.
Bears Say
Development StageNRx Pharmaceuticals is a developmental-stage biotechnology company working broadly in suicidal ideation and behavior, a large area of unmet need that has seen essentially no improvement in treatment outcomes in 50 years.
Market CompetitionThere is no medicine approved to treat patients with bipolar depression suffering suicidal ideation, presenting a large market potential.
---
Ownership Overview
8.97% Insiders
1.82% Mutual Funds
3.11% Other Institutional Investors
82.16% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.10 and its highest was $6.01 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is $34.68M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is May 20, 2025 which is in 22 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on Mar 17, 2025. The company reported -$0.712 earnings per share for the quarter, missing the consensus estimate of -$0.367 by -$0.345.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is -0.3.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 16,915,648 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.712 in its last earnings report, missing expectations of -$0.367. Following the earnings report the stock price went down -12.766%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in NRXP
---
NRX Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.50 (793.72% Upside)
$18.50 (793.72% Upside)
Hedge Fund Trend
Increased
By 50.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $46.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.72%
12-Months-Change
Fundamentals
Return on Equity
108.28%
Trailing 12-Months
Asset Growth
-50.09%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
---
NRXP Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in drug development, potential strategic partnerships, and financial improvements, particularly with the expansion of HOPE Therapeutics. However, challenges remain due to the unsupportive capital market environment, low cash reserves, and regulatory complexities in clinic acquisitions. Despite these challenges, the positive developments and strategic initiatives outweigh the negatives.Read More>---
NRXP Stock 12 Month Forecast
Average Price Target
$18.50
▲(793.72% Upside)
Technical Analysis
Atara Biotherapeutics
―
Reviva Pharmaceuticals Holdings
―
Coeptis Therapeutics Holdings
―
RenovoRx
―
Radiopharm Theranostics Limited Sponsored ADR
―
Best Analysts Covering NRXP
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-23.13%
reiterated a buy rating 5 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -23.13% per trade.
---